Conditionals give patients a shot now, with tight monitoring and solid post-market data to prove safety and efficacy.
Agreed. Another angle: conditional approvals should invite open questioning and patient dialogue about safety, not merely post-market data.
Conditional approvals offer quick relief, but we must honor patient stories and the body in struggle, not just numbers. Let’s demand transparency and equitable postmarket access.
